(HealthDay)—There’s good news for the millions of Americans who’ve already received a dose or two of Moderna’s COVID-19 vaccine: New research shows the vaccine should protect against illness for at least six months.
The new study tracked 33 participants in the trials that led to the vaccine’s approval. Six months after having received their second vaccine dose, “antibody activity remained high in all age groups,” according to a team led by Nicole Doria-Rose of the U.S. National Institute of Allergy and Infectious Diseases (NIAID).
Her group published their findings April 6 in the New England Journal of Medicine.
The reassuring results follow on similar findings for the other major two-dose vaccine included in the U.S. vaccine rollout, made by Pfizer/BioNTech. Trial results released April 1 by the companies found that their vaccine remains more than 91% effective six months after people get their second dose.
The new results from Moderna are based on 33 people ranging in age from 18 to older than 71. The study found that while everyone maintained high levels of infection-fighting immune system antibodies in blood samples, levels did seem to fall according to the increasing age of participants.
For example, while levels (“titers”) of antibodies averaged over 92,000 in vaccinated people aged 18 to 55 at six months after full immunization, they dropped to an average of about 62,000 in people aged 56 to 70, and to just over 49,000 in people aged 71 and older.
Still, all participants “had detectable [antibody] activity” six months on, and that was found on three distinct types of blood tests, the NIAID-led team said.
Dr. Amesh Adalja is an expert in virology and senior scholar at the Johns Hopkins Center for Health Security, in Baltimore. Reviewing the new report, he said that immunity might last even longer than the six-month period the researchers were able to report on now.
“As companies conduct natural history studies to look at the duration of antibodies and other correlates of immunity in coronavirus-vaccinated individuals, it is expected that we will see that immunity lasts for a considerable amount of time,” Adalja said. “As the duration of the studies increases, I anticipate we will find that immunity lasts for over a year.”
In the meantime, Doria-Rose and her colleagues said that “ongoing studies are monitoring immune responses beyond six months as well as determining the effect of a booster dose to extend the duration and breadth of activity against emerging viral variants.”
Follow the latest news on the coronavirus (COVID-19) outbreak
There’s more on COVID-19 vaccination at the U.S. Centers for Disease Control and Prevention.
Copyright © 2021 HealthDay. All rights reserved.
Moderna COVID vaccine offers protection for at least 6 months, study finds (2021, April 6)
retrieved 7 April 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- Bingeing, Stress Snacking: How the Pandemic Is Changing Eating Habits - April 16, 2021
- A method to assess COVID-19 transmission risks in indoor settings - April 16, 2021
- Later School Start Times Mean Better-Rested Kids: Study - April 16, 2021
- हरदा में 26 अप्रैल तक रहेगा कोरोना कर्फ्यू - April 16, 2021
- Ten reasons why the coronavirus is airborne - April 16, 2021
- Your Zip Code Could Help or Harm Your Brain - April 16, 2021
- 10वीं और 12वीं के प्रवेश-पत्रों में 10 मई तक करा सकेंगे संशोधन - April 16, 2021
- Temporal link between medical cannabis for epilepsy and early puberty - April 16, 2021
- COVID Plus ‘Bleeding’ Stroke Doubles a Patient’s Death Risk - April 16, 2021
- खाद्य मंत्री श्री सिंह ने अनूपपुर में की कोरोना व्यवस्थाओं की समीक्षा - April 16, 2021